Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cryo-Cell InternationalSTU:ZCY -2.24%53 OCF Margin % is 23.74% as of May. 2026, which is 8% above its 10-year median of 22.05. GuruFocus rates STU:ZCY with a GF Score™ of 53/100 and a GF Value™ of €4.24. The stock has 4 warning signs investors should review. Among 666 Healthcare Providers & Services companies, Cryo-Cell International ranks better than 83.48% on this metric.
The historical rank and industry rank for Cryo-Cell International's OCF Margin % or its related term are showing as below:
STU:ZCY'
s OCF Margin % Range Over the Past 10 Years
Min: 17.36 Med: 22.05 Max: 28.46
Current: 20.32
During the past 13 years, the highest OCF Margin % of Cryo-Cell International was 28.46%. The lowest was 17.36%. And the median was 22.05%.
STU:ZCY's OCF Margin % is ranked better than 83.48% of 666
companies
in the Healthcare Providers & Services industry
Industry Median: 8.27
vs STU:ZCY: 20.32
Cryo-Cell International OCF Margin % Related Terms
Cryo-Cell International OCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:ZCY vs EHSI, PIII, CCM: OCF Margin % Comparison
For the Medical Care Facilities subindustry, Cryo-Cell International's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International OCF Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International (STU:ZCY) has a OCF Margin % of 23.74% as of May. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Cryo-Cell International and its competitors. This is near median its historical median of 22.05. Over the past decade, Cryo-Cell International's OCF Margin % has ranged from 17.36 to 28.46. According to the industry distribution chart, Cryo-Cell International ranks #110 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 16.5%.
Is Cryo-Cell International's OCF Margin % too high?
Cryo-Cell International's current OCF Margin % of 23.74% is near median its 10-year median of 22.05. Over the past 10 years, this metric has ranged from a low of 17.36 to a high of 28.46. The Healthcare Providers & Services industry median OCF Margin % is 8.27. Cryo-Cell International's value of 23.74% is 187.1% above this industry median. Based on the distribution chart, Cryo-Cell International ranks #110 out of 666 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Cryo-Cell International has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's OCF Margin % compare to EHSI and PIII?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #110 out of 666 companies for OCF Margin %. This places Cryo-Cell International in the top 17% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 8.27. Cryo-Cell International's value of 23.74% is 187.1% above this benchmark. Historically, Cryo-Cell International's own OCF Margin % has ranged from 17.36 to 28.46 over the past decade. While the company's 10-year median is 22.05 vs. the industry median of 8.27, Cryo-Cell International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Healthcare Providers & Services company?
The median OCF Margin % among Healthcare Providers & Services companies is 8.27, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryo-Cell International's current OCF Margin % of 23.74% is 187.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median OCF Margin % is 8.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current OCF Margin % is 23.74%, which is near median its own 10-year median of 22.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Cryo-Cell International (STU:ZCY) has a current OCF Margin % of 23.74%. The stock's GF Value™ is €4.24, compared to a current price of €2.62 — trading 38.2% below its estimated fair value. The current OCF Margin % is 23.74%, which is near median its 10-year median of 22.05 and 187.1% above the Healthcare Providers & Services industry median of 8.27. Cryo-Cell International's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Cryo-Cell International (STU:ZCY), the current OCF Margin % is 23.74% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (STU:ZCY) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of €2.62 is trading 38.2% below its estimated GF Value™ of €4.24.
Key valuation signals for STU:ZCY:
OCF Margin %: 23.74% (near median its 10-year median of 22.05)
GF Value™: €4.24 vs. price of €2.62 (38.2% below fair value)
Industry Position: 187.1% above the Healthcare Providers & Services median (#110 of 666)
No single metric tells the full story. See the STU:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
53GF Score
Get the complete analysis for STU:ZCY
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ZCY has been successfully added to your 
